Hartaj Singh
Stock Analyst at Oppenheimer
(1.42)
# 3,416
Out of 4,924 analysts
105
Total ratings
38.46%
Success rate
-11.5%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $16.26 | +127.55% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $555.13 | +62.12% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $110.28 | +13.35% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $385.65 | - | 17 | Dec 19, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $6.93 | +304.04% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $302.41 | +98.41% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $26.71 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $2.71 | +269.00% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.59 | +3,673.58% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.55 | +482.52% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.46 | +2,639.73% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $5.95 | +269.75% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.59 | +40,780.50% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $28.52 | +5.19% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $16.26
Upside: +127.55%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $555.13
Upside: +62.12%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $110.28
Upside: +13.35%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $385.65
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $6.93
Upside: +304.04%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $302.41
Upside: +98.41%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $26.71
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $2.71
Upside: +269.00%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.59
Upside: +3,673.58%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.55
Upside: +482.52%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.46
Upside: +2,639.73%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $5.95
Upside: +269.75%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.59
Upside: +40,780.50%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $28.52
Upside: +5.19%